The p38 MAPK Inhibitor SB203580 Abrogates Tumor Necrosis Factor-Induced Proliferative Expansion of Mouse CD4+Foxp3+ Regulatory T Cells

Tianzhen He1, Shuoyang Liu1, Shaokui Chen1, Jingyi Ye1, Xueqiang Wu2, Zhaoxiang Bian3 and Xin Chen1*

1 State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR, China, 2 Department of Oncology, Beijing Aerospace General Hospital, Beijing, China, 3 School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong SAR, China

There is now compelling evidence that tumor necrosis factor (TNF) preferentially activates and expands CD4+Foxp3+ regulatory T cells (Tregs) through TNF receptor type II (TNFR2). However, it remains unclear which signaling transduction pathway(s) of TNFR2 is required for the stimulation of Tregs. Previously, it was shown that the interaction of TNF–TNFR2 resulted in the activation of a number of signaling pathways, including p38 MAPK, NF-κB, in T cells. We thus examined the role of p38 MAPK and NF-κB in TNF-mediated activation of Tregs, by using specific small molecule inhibitors. The results show that treatment with specific p38 MAPK inhibitor SB203580, rather than NF-κB inhibitors (Sulfasalazine and Bay 11-7082), abrogated TNF-induced expansion of Tregs in vitro. Furthermore, upregulation of TNFR2 and Foxp3 expression in Tregs by TNF was also markedly inhibited by SB203580. The proliferative expansion and the upregulation of TNFR2 expression on Tregs in LPS-treated mice were mediated by TNF–TNFR2 interaction, as shown by our previous study. The expansion of Tregs in LPS-treated mice were also markedly inhibited by in vivo treatment with SB203580. Taken together, our data clearly indicate that the activation of p38 MAPK is attributable to TNF–TNFR2-mediated activation and proliferative expansion of Tregs. Our results also suggest that targeting of p38 MAPK by pharmacological agent may represent a novel strategy to up- or downregulation of Treg activity for therapeutic purposes.

Keywords: tumor necrosis factor, TNF receptor type II, p38 MAPK, CD4+Foxp3+ regulatory T cells, proliferation

INTRODUCTION

CD4+Foxp3+ regulatory T cells (Tregs) are crucial for the maintenance of immune homeostasis and for the prevention of autoimmune responses (1). They also play a major role in immune evasion of cancer by dampening immune responses against tumor (2). Targeting Tregs has become a strategy in the treatment of major human diseases, such as cancer, allergic and autoimmune diseases, transplantation rejection, and GVHD (3). A thorough understanding of biological pathways that regulate Treg function is a prerequisite for the up- or downregulation of Treg activity for therapeutic purposes.

We (Xin Chen and Joost J. Oppenheim) for the first time report that tumor necrosis factor-alpha (TNF) can activate Tregs through TNF receptor type II (TNFR2), one of TNF receptors, which is
preferentially expressed by Tregs (4). Furthermore, we found that expression of TNFR2 identifies the maximally potent suppressive human and mouse Treg subsets (5, 6). In contrast, Tregs without TNFR2 expression only had minimal or no suppressive activity (5, 7, 8). Moreover, TNF–TNFR2 signaling is important for the phenotypical stability of Tregs, including Foxp3 expression (4, 8, 9). The notion that TNF–TNFR2 signaling plays a decisive role in the activation, expansion, and phenotypical stability of Tregs is now supported by compelling evidences from other groups (10–21). Nevertheless, which signaling transduction pathway(s) of TNFR2 is required for Treg-stimulatory effect of TNF remains unknown.

The biological functions of TNF are transduced by two receptors, TNFR1 (p55) and TNFR2 (p75) (22). In contrast to the ubiquitous expression of TNF receptor type 1 (TNFR1), TNFR2 is mainly expressed by lymphocytes (23). Signal transduction by TNFR1 has been intensively investigated and well defined, while the TNFR2 signaling pathway is less well understood (24). So far, three signaling pathways of TNFR2 in T lymphocytes have been documented, including IKK/NF-κB, MAPK (Erk1/2, p38, JNK), and PI3K/Akt pathways (25, 26). Previously, p38 MAPK signaling pathway has been shown to play a key role in the immunosuppressive function of induced Tregs (iTregs) in both in vitro and in vivo studies (27–29). It was also reported that inhibition of p38 MAPK signaling was able to reduce immunosuppression of iTregs on T effs, and consequently enhanced antitumor immune responses (29, 30). It has been shown that TNF stimulation resulted in the activation of p38 MAPK, in addition to the activation of NF-κB, in Tregs (31, 32). Thus, we hypothesized that p38 MAPK signaling pathway may also be attributable to the activation and proliferation of Foxp3+ naturally occurring Tregs (nTregs) by TNF–TNFR2 interaction.

In this study, we investigated the effect of SB203580, a p38 MAPK-specific inhibitor, on the expansion of Tregs induced by the interaction of TNF–TNFR2 in both in vitro and in vivo experimental settings. The results showed that SB203580 potently inhibited TNF-induced proliferative expansion of Tregs. Furthermore, other stimulatory effects of TNF on Tregs, such as upregulation of TNFR2 and Foxp3 expression were also abrogated by SB203580. Therefore, p38 MAPK represents a major component of signaling pathway of TNFR2 in the activation of Tregs.

RESULTS

SB203580 Inhibits TNF-Induced Proliferation of Tregs In Vitro

We firstly examined the in vitro effect of p38 MAPK-specific inhibitor SB203580 (33) on the expansive proliferation of Tregs induced by TNF. To this end, CD4+ T cells were purified by MACS from spleen and LNs of normal mice. The cells were cultured with IL-2 to maintain their survival (34). Consistent with our previous report (4, 17), addition of TNF preferentially stimulated the proliferation of Tregs, resulting in proliferation of greater than 60% of Tregs (Figure 1A). Consequently, the absolute number of Tregs in the cultured CD4+ T cells was increased twofold by TNF stimulation (Figure 1E). As shown in Figures 1B–C, in a concentration range of 1–25 µM, SB203580 inhibited the TNF-induced proliferation of Tregs in a dose-dependent manner, with a percent inhibition of 32.0–73.2% (p < 0.05–0.001). The proportion of Foxp3+ Tregs in the cultured CD4+ T cells was also markedly reduced by SB203580 treatment, with a percent inhibition of 24.9–47.05% (Figure 1D, p < 0.05–0.01). Furthermore, the absolute number of Tregs in each well was markedly reduced (Figure 1E, p < 0.05). In contrast, treatment with two NF-κB inhibitors [Sulfasalazine (35) and Bay 11-7082 (36)] failed to inhibit TNF-induced proliferative expansion of Tregs in the cultured CD4+ T cells (Figures 2A–F). These results suggest that the activation of p38 MAPK, rather than the activation of NF-κB, is required for the proliferative expansion of Tregs triggered by TNFR2 signaling. Treatment with SB203580 in the concentration range used in our in vitro study did not induce cell death (Figure S1 in Supplementary Material). Furthermore, SB203580 treatment did not reduce the number of Tregs in CD4+ T cells cultured with IL-2 alone (Figure S2 in Supplementary Material). These data exclude the possibility that the inhibitory effect of SB203580 was based on the cytotoxic effect.

SB203580 Downregulates TNFR2 Surface Expression on TNF-Stimulated Tregs

The surface expression levels of TNFR2 are correlated with immunosuppressive function of Tregs (5, 6). Previously, we showed that treatment with TNF preferentially upregulates TNFR2 expression on Tregs (37). To determine if p38 MAPK pathway plays a role in the upregulation of TNFR2 expression on Tregs, MACS-purified CD4+ T cells were cultured with IL-2, with or without TNF. The cells were treated with SB203580 (1–25 µM). As shown in Figure 3A, the treatment with TNF upregulated TNFR2 expression on Tregs by ~2-folds, as compared with IL-2 cultured alone. TNF-induced upregulation of TNFR2 expression was inhibited by SB203580 in a dose-dependent manner (Figures 3A, B, p < 0.01–0.001), with a percent inhibition of 32.3–62.6% (Figure 3C, p < 0.01–0.001). Thus, inhibition of p38 MAPK with SB203580 can inhibit surface expression of TNFR2 on TNF-treated Tregs.

SB203580 Abrogates TNF-Induced Upregulation of Foxp3 Expression in Tregs

TNF–TNFR2 interaction is also crucial for the phenotype stability of Tregs, in term of Foxp3 expression, both in in vitro and in vivo settings (8). We thus examined the effect of SB203580 on Foxp3 expression by TCR-stimulated Tregs. To this end, mouse CD4+CD25+ T cells were flow-sorted and stimulated with plate-bound anti-CD3 Ab and soluble anti-CD28 Ab for 3 days, a known condition, which can downregulate Foxp3 expression (8). Treatment with the exogenous TNF could partially maintain Foxp3 expression (Figures 4A–C), consistent with our previous report (8). The levels of Foxp3 expression on per cell basis (MFI) and the proportion of Foxp3-expressing cells were increased by twofold after TNF treatment. These effects of TNF were largely abrogated by the treatment of SB203580 (Figures 4A–C). It is worth noting that SB203580, in the absence of TNF, did...
Fig URE 1 | SB203580 (SB) inhibits tumor necrosis factor (TNF)-mediated expansion of regulatory T cells (Tregs) in vitro. CD4+ T cells were purified from LNs and spleen of normal C57BL/6J mice by MACS. The cells were labeled with CFSE and cultured in the presence of IL-2 (10 ng/mL), or IL-2 + TNF (10 ng/mL, each), with medium alone or with different concentrations of SB203580 (SB, 1, 5, 10, and 25 µM). After 72 h, the proliferation of Tregs and the proportion of Foxp3+ cells were analyzed by FACS, based on CFSE expression and Foxp3 expression. The absolute number of Foxp3-expressing Tregs was calculated. (a) In the presence of IL-2, TNF preferentially stimulated the proliferation of Tregs. (b,c) SB203580 blocked TNF-mediated proliferation of Tregs. Analysis was gated on Foxp3+ Tregs. (d) SB203580 decreased the proportion of Foxp3+ Tregs in the cultured CD4+ T cells. (e) SB203580 reduced the absolute number of Tregs in the cultured CD4+ T cells. (a,B) Show the typical FACS plots. The number in the histogram indicates the proportion of gated cells (%). (c,D) Show the summary of results (N = 3, means ± SEM). By comparison with “TNF + IL-2” group, *p < 0.05, **p < 0.01, ***p < 0.001. Data shown are representatives of at least three separate experiments with similar results.

not downregulate Foxp3 expression in Tregs (Figure S2 in Supplementary Material).

SB203580 Inhibits In Vivo Expansion of Tregs in LPS-Treated Mice

Previously, we showed that TNF–TNFR2 interaction is responsible for LPS-induced proliferation of Tregs in mice (37). More recently, we observed that LPS treatment was able to markedly upregulate the expression of transmembrane TNF on dendritic cells (DCs), and such DCs potently stimulated the proliferation of Tregs (data not shown). Therefore, LPS-treated mice were used to examine if SB203580 had the in vivo activity to inhibit TNF-induced expansion of Tregs. As shown in Figures 5A,C, the proportion of Foxp3+ cells in splenic CD4+ T cells was increased from 14.6% in control mice to 18.6% in mice 24 h after LPS treatment (p < 0.01). Similarly, the proportion of Foxp3+ cells in CD4 T cells present in peripheral blood and
Figure 2 | Effect of NF-κB inhibitors on tumor necrosis factor (TNF)-mediated proliferative expansion of regulatory T cells (Tregs). CD4+ cells were purified from LNs and spleen of normal C57BL/6J mice by MACS. The cells were labeled with CFSE and cultured in the presence of IL-2 (10 ng/mL), or IL-2 + TNF (10 ng/mL, each), with medium alone or with different concentrations of Sulfasalazine (Sul, 1, 10, 50, 100 µM) or Bay 11-7082 (Bay, 0.5, 1, 2, and 4 µM). After 72 h, the proliferation of Tregs and the absolute number of Foxp3+ cells were analyzed by FACS, based on CFSE expression and Foxp3 expression. (A,B) Typical FACS analysis of Treg proliferation, as shown by dilution of CFSE expression (gating on Foxp3+ cells). The number in the histogram indicates the proportion of gated cells, e.g., replicating cells (%). (C,D) The summary of proportion of replicating Tregs. (E,F) The absolute number of Treg cells per well. Data shown in (C–F) are representatives of at least three separate experiments with similar results (N = 3, means ± SEM).
lymph nodes following intraperitoneal LPS injection was also increased compared with control mice (Figure 5C). The expressions of Ki-67, an indicator of replicating cells, and TNFR2 were markedly increased in the splenic Tregs (Figures 5B,E and 6A,C, p < 0.01–0.05), which is consistent with our previous report (7). Since the proportion of Tregs were increased in all observed tissues, which was accompanied by the upregulation of Ki-67, we concluded that the increased number of Tregs in LPS-treated mice was resulted from the proliferative expansion through the interaction of TNF–TNFR2, rather than resulted from the redistribution or alteration of trafficking pattern of Tregs (37). LPS treatment also increased the absolute number of Tregs in spleen by ~1.5-fold (Figure 5D, p < 0.01). Treatment with single dose of SB203580 (25 mg/kg/day, i.p.) immediately after LPS treatment completely inhibited LPS-induced expansion of Tregs (Figure 5A). Moreover, LPS-induced upregulation of Ki-67 and TNFR2 expression on Tregs was also completely abrogated by the treatment of SB203580 (Figures 5B,E and 6A,C). The inhibitory effect of SB203580 on the proliferative expansion of Tregs, as indicated by the proportion of Foxp3+ Tregs and their Ki-67 expression, in LPS-treated mice could last for at least 72 h (Figure S3 in Supplementary Material). CD152 (CTLA4) is a characteristic marker and an effector molecule of Tregs. Expression of CD152 in Tregs was upregulated by LPS-treatment (Figures 6B,D, p < 0.001), and the elevation of CD152 expression in LPS-treated mice was completely abrogated by SB203580 treatment (Figures 6B,D). Therefore, SB203580 has both in vitro and in vivo activity in the inhibition of TNFR2-mediated activation and expansion of Tregs.

**DISCUSSION**

The p38 MAPK signaling pathway is known to play a key role in mediating the responses of mammalian cells to LPS stimulation (38), including production of TNF by LPS-treated macrophages (39). The activation of p38 MAPK contributes to
SB203580 inhibits Foxp3 expression in tumor necrosis factor (TNF)-treated regulatory T cells. FACSorted CD4+CD25+ T cells were stimulated with plate-bound anti-CD3 and soluble anti-CD28 Abs, in the presence or absence of TNF (10 ng/mL), with or without 25 µM SB203580 for 3 days. Foxp3 expression and ratio of Foxp3+ cells were analyzed by FACS.

**A** Typical histograms of Foxp3 expression. Number in the histogram indicates the proportion of gated cells.

**B** Summary of Foxp3 expression (MFI. N = 3, means ± SEM).

**C** Summary of proportion of Foxp3-expressing cells (N = 3, means ± SEM). By comparison with TNF group (without SB203580), *p < 0.05, **p < 0.01, ***p < 0.001. Data shown are representatives of at least three separate experiments with similar results.

It has been shown that TNF–TNFR2 interaction was able to activate p38 MAPK pathway in T cells through activation of Syk protein tyrosine kinase (48). Nagar/Goldstein and colleagues (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18893) indicated that both p38 MAPK pathway and NF-κB pathway in Tregs were markedly activated after TNF stimulation (Tables S1 and S2 in Supplementary Material). Recent evidence also showed that TNFR2-specific TNF-variant scTNF(143N/145R) treatment markedly activated p38 MAPK and NF-κB in purified human Tregs (32). In our study, small molecule inhibitors of p38 MAPK and NF-κB pathways, namely SB203580, Sulfasalazine, and Bay 11-7082, were employed to determine which TNFR2 signaling pathway is required for Treg expansion induced by TNF–TNFR2 interaction. Previously, SB203580 was well characterized as a specific p38 MAPK inhibitor (33), and Sulfasalazine was a specific inhibitor of NFκB activation (35), while Bay 11-7082 was a direct inhibitor of IKK and thus inhibits the signal-induced nuclear translocation of NF-κB (36). These three compounds have been frequently used by investigators to study the effect of inhibition of p38 MAPK and NF-κB in T cells, including Tregs (27, 46, 47).

We confirmed that p38 MAPK and canonical NF-κB pathways in Treg cells were activated by TNF stimulation. Furthermore, such upregulation of p38 MAPK and NF-κB activity could be potently inhibited by SB203580, Sulfasalazine, and Bay 11-7082, respectively (Figure S4 in Supplementary Material). Our study clearly shows that p38 MAPK-specific inhibitor SB203580, but not sulfasalazine nor Bay 11-7082, potently inhibited TNF-induced expression, expansion of TNFR2 and Foxp3 on Tregs in both in vitro and in vivo experiments. Our results thus provide...
SB203580 inhibits expansion of regulatory T cells (Tregs) in LPS-treated mice. C57BL/6J mice were injected with 200 µg of LPS (i.p.) or PBS, and treated with or without SB203580 (25 mg/kg/day, i.p.) immediately after LPS challenge. All mice were sacrificed 24 h after LPS treatment. Blood, spleen, and lymph nodes were harvested. The proportion of Foxp3+ Tregs in CD4+ T cells and expression of Ki-67 by Tregs were analyzed by FACS, gating on Foxp3+ cells. The absolute number of Tregs was calculated. (A) Expression of Foxp3 by CD4+ T cells. Number shows the proportion of gated cells. (B) Expression of Ki-67 by Foxp3− and Foxp3+ cells. Number shows the proportion of positive cells in the respective quadrants. (A,B) Typical FACS plots were shown. (C) Summary of proportion of Tregs in CD4+ T cells in the peripheral blood, spleen and LNs. (D) Summary of absolute number of Tregs in the spleen. (E) Ki-67 expression (MFI) by Foxp3+ Tregs. Data (means ± SEM) in (C) were pooled from three separate experiments (spleen and lymph nodes: N = 9, peripheral blood: N = 6), and in (D,E) (N = 3) were representatives of at least three separate experiments with similar results. By comparison with LPS alone group, *p < 0.05, **p < 0.01, ***p < 0.001.
clear evidence that p38 MAPK may represent an important component of TNFR2 signaling pathway in the activation and expansion of Tregs induced by TNF.

In our in vitro studies, IL-2 was used to maintain the survival of cultured T cells. Previously, we showed that in this in vitro culture system, TNF-induced proliferation of Tregs was independent of IL-2 (37). This conclusion was further substantiated by the studies from other groups (12, 49). Thus, inhibition of Treg proliferation by SB203580 is mainly achieved by blockade of p38 MAPK activity triggered by TNF–TNFR2 signaling. This idea is supported by the observation that SB203580 did not reduce the number of Tregs in CD4 T cells cultured with IL-2 alone (Figure S2 in Supplementary Material). Nevertheless, IL-2 and TCR/CD28 co-stimulation can also induce the activation of p38 MAPK pathway (50, 51) and can also stimulate the activation and expansion of Tregs (52, 53). Such effect of IL-2 and TCR/CD28 may also contribute to in vivo expansion of Tregs in the inflammatory condition, such as in mice treated with LPS. If this is the case, targeting of p38 MAPK may be able to block Tregs expansion induced by multiple signaling pathways.

Elimination of Treg activity, by either reducing their number or downregulating their immunosuppressive function, has become a strategy to enhance the efficacy of cancer therapy (54). Since TNFR2 signaling plays a crucial role in the activation and expansion of Tregs, the major component of TNFR2 signaling pathway responsible for Treg-stimulatory effect may be harnessed to modulate Treg activity. Recent study indicates that TNFR2 is an emerging target of cancer immunotherapy (15, 55). As suggested by our study, inhibition of p38 MAPK may enhance the efficacy of tumor immunotherapy by eliminating Treg activity. Interestingly, it was shown that inhibition of p38 MAPK with SB203580 markedly enhances DC’s capacity to activate Teffs and overcome Treg-mediated suppression, and consequently promote antitumor immune response (30, 56, 57). Thus, p38 MAPK inhibitors may be useful as an immune adjuvant to enhance the
efficacy of tumor immunotherapy by simultaneously acting on both Tregs and DCs.

The rationale of development of p38 MAPK inhibitor as therapeutic agent is largely based on the idea that inhibition of p38 MAPK would inhibit the production of TNF (39), since anti-TNF biologics have been shown great success in the treatment of autoimmune inflammatory diseases (58). Although preclinical studies suggest that p38 MAPK inhibitors had therapeutic potential in the treatment of inflammatory diseases in animal model, such as collagen-induced arthritis (59) and experimental allergic encephalomyelitis (60); however, the subsequent clinical trials have generally failed (40). Moreover, treatment with p38 MAPK inhibitors has the potential to induce additional inflammatory responses in RA patients (61). One possibility raised by our studies is that attenuation of Treg activity through interruption of TNF–TNFR2 interaction might be related to the failure of clinical trials designed to examine the effect of p38 MAPK inhibitors in the treatment of chronic inflammatory diseases.

Taken together, our data clearly show that p38 MAPK inhibitor SB203580 has the capacity to abrogate TNF-induced proliferative expansion, expression of TNFR2 and Foxp3 on Tregs. The results suggest that p38 MAPK may represent a key component of TNFR2 signaling pathway, which is required for the activation and expansion of Tregs. Thus, p38 MAPK pathway may be a therapeutic target to enhance the efficacy of cancer immunotherapy by eliminating Treg activity and other immunosuppressive mechanisms, and this possibility should be addressed in the future study.

MATERIALS AND METHODS

Mice and Reagents

Female wildtype (WT) C57BL/6J (8–12 weeks old) were provided by the Animal Facility of University of Macau. The animal study protocol was approved by Animal Research Ethics Committee of University of Macau. Antibodies purchased from BD Pharmingen (San Diego, CA, USA) consisted of PerCP-Cy5.5 anti-mouse CD3 (145-2C11), PE anti-mouse CD4 (GK1.5), PE anti-mouse CD120b/TNFR2 (TR75-89), PerCP-Cy5.5 anti-mouse CD25 (PC61), PE anti-mouse CD152 (UC10-4F10-11). Antibodies purchased from eBioscience include PE-Cy7 anti-mouse CD25 (PC61), APC anti-mouse/rat Foxp3 staining set (FJK-16s). Functional grade purified hamster anti-mouse CD3e (145-2C11), Functional grade purified hamster anti-mouse CD28 (37.51), recombinant mouse IL-2 and TNF were obtained from BD Pharmingen. Bay 11-7082 (Cat#: B5556), and Lipopolysaccharides (rough strains) from Salmonella (LPS) (Cat#: L9764) was purchased from Sigma-Aldrich. Sulfasalazine (Cat#: S1576) and SB203580 (Cat#: S1076) was obtained from Selleckchem. LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit (for 633 or 635 nm, L10119) was ordered from Thermo Fisher Scientific.

Cell Purification and In Vitro Cell Culture

Mouse lymphocytes were harvested from spleens, axillary lymph nodes, inguinal lymph nodes, and mesenteric lymph nodes. CD4+ T cells were purified from lymphocytes by using CD4 (L3T4) microbeads (Miltenyi Biotec, 130-097-145) and MS column (Miltenyi Biotec). MACS-Purified CD4+ cells were labeled with CFSE and cells (5 × 10^4 cells/well) were cultured in a 96-well plate, then stimulated with IL-2 or IL-2 plus TNF, in the presence or absence of SB203580 (1–25 µM) for 3 days. Proliferation of Tregs was assessed by CFSE dilution assay, and the proportion of Foxp3+ cells in CD4+ subset and TNFR2 expression on Tregs were analyzed with FACS. In some experiments, FACS-sorted CD4+CD25+ cells (cells purity: 98%, 5 × 10^4 cells/well) were stimulated with plate-bound anti-CD3e Ab (10 µg/mL) and soluble anti-CD28 Ab (2 µg/mL) in the presence of TNF (10 ng/mL) or medium alone, with or without 25 µM SB203580, for 3 days. Expression of Foxp3 and TNFR2 were analyzed by FACS.

In Vivo Administration of LPS and SB203580

C57BL/6J mice were injected intraperitoneally (i.p.) with 200 µg of LPS in 0.2 mL PBS. Some mice were treated with SB203580 (25 mg/kg, i.p.) immediately after LPS treatment. SB203580 were dissolved in a stable solvent system (4% DMSO, 30% PEG 300, 5% Tween 80, and 61% ddH2O). After 24 and 72 h, mice were sacrificed. The spleens, lymph nodes at axillary, inguinal, and mesenteric regions, and blood were harvested for FACS analysis.

Flow Cytometry

After blocking FcR, cells were incubated with appropriately diluted antibodies and finally suspended in FACS buffer for cytometric analysis. Acquisition was performed by BD FACSCanto II and BD FACS Aria™ Fusion flow cytometer. Data analysis was conducted by using FlowJo software (Tree Star Inc., Ashland, OR, USA).

Western Blot

MACS-purified CD4+CD25+ T cells were stimulated with TNF (100 ng/mL), with or without selected inhibitors [SB203580 (SB), Bay 11-7082 (Bay), Sulfasalazine (Sul)] for 30 min. The cells were homogenized in RIPA buffer containing a cocktail of proteinase and phosphatase inhibitors. Protein samples were separated on a SDS-PAGE gradient gel (4–12% Bis-Tris protein gel; Thermo Fisher Scientific) and transferred to PVDF membranes. The blots were blocked with 5% BSA for 1 h and incubated with phospho-p38 antibody (1:1,000; Cell Signaling Technology) and phospho-NF-κB p65 antibody (1:1,000; Cell Signaling Technology) overnight at 4°C. The blots were then incubated in HRP-conjugated secondary antibody (1:3,000) for 1 h at room temperature, developed in ECL solution (Thermo Fisher Scientific) for 1 min, and exposed by G-Box imager. The blots were then incubated in stripping buffer (Thermo Fisher Scientific) at 37°C for 15 min and reprobing with IκBα antibody (1:1,000; Cell Signaling Technology) or p38 antibody (1:1,000; Cell Signaling Technology) or NF-κB p65 antibody (1:1,000; Cell Signaling Technology) or GAPDH antibody (1:3,000; Cell Signaling Technology).
**Statistical Analysis**

Comparisons of two groups of data were analyzed by t test using GraphPad Prism 6.0. Comparisons of more than two groups of data were analyzed by one-way ANOVA by using GraphPad Prism 6.0 (GraphPad, San Diego, CA, USA).

**ETHICS STATEMENT**

This study was carried out in accordance with the recommendations of approved guidelines of Animal Research Ethics Committee, University of Macau. The protocol was approved by the Animal Research Ethics Committee of University of Macau.

**AUTHOR CONTRIBUTIONS**

TH, SL, SC, JY, and XW performed the experiments. TH, ZB, and XC designed the experiments and wrote the manuscript. All authors agree to the submission of the manuscript.

**REFERENCES**

1. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell (2008) 133(5):775–87. doi:10.1016/j.cell.2008.05.009
2. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 6(4):295–307. doi:10.1038/nri1806
3. Perdigoto AL, Chatenoud L, Bluestaue JA, Herold KC. Inducing and administering Tregs to treat human disease. Front Immunol (2015) 6:6554. doi:10.3389/fimmu.2015.00654
4. Chen X, Baumel M, Mannel DN, Howard OM, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol (2007) 179(1):154–61. doi:10.4049/jimmunol.179.1.154
5. Chen X, Subleski JJ, Kopf H, Howard OM, Mannel DN, Oppenheim JJ. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+Foxp3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol (2008) 180(10):6467–71. doi:10.4049/jimmunol.180.10.6467
6. Chen X, Subleski JJ, Hamano R, Howard OM, Withrow RH, Oppenheim JJ. Co-expression of TNFR2 and CD25 identifies more of the functional CD4+Foxp3+ regulatory T cells in human peripheral blood. Eur J Immunol (2010) 40(4):1099–106. doi:10.1002/eji.200940222
7. Chen X, Hamano R, Subleski JJ, Hurwitz AA, Howard OM, Oppenheim JJ. Expression of costimulatory TNFR2 induces resistance of CD4+Foxp3+ conventional T cells to suppression by CD4+Foxp3+ regulatory T cells. J Immunol (2010) 185(1):174–82. doi:10.4049/jimmunol.0903548
8. Chen X, Wu X, Zhou Q, Howard OM, Neta MG, Oppenheim JJ. TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T cell phenotype in the inflammatory environment. J Immunol (2013) 190(3):1076–84. doi:10.4049/jimmunol.1202659
9. Zhou Q, Hu Y, Howard OM, Oppenheim JJ, Chen X. In vitro generated Th17 cells support the expansion and phenotypic stability of CD4(+)Foxp3(+) regulatory T cells in vivo. Cytokine (2014) 65(1):56–64. doi:10.1016/j.cyt.2013.09.008
10. Ma HL, Napierata L, Stedman N, Benoit S, Collins M, Nickerson-Nutter C, et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum (2010) 62(2):430–40. doi:10.1002/art.27203
11. Mougiaxakos D, Johansson CC, Jitschin R, Bottcher M, Kiessling R. Increased thioredoxin-1 production in human naturally occurring regulatory T cells confers enhanced tolerance to oxidative stress. Blood (2011) 117(3):857–61. doi:10.1182/blood-2010-09-307041
12. Grinberg-Bleyer Y, Saadoun D, Baeyens A, Billard F, Goldstein JD, Grégoire S, et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest (2010) 120(12):4558–68. doi:10.1172/JCI42945
13. Kleijwegt FS, Laban S, Dukunkerken G, Joosten AM, Zaldumbide A, Nikolic T, et al. Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol (2010) 185(3):1412–8. doi:10.4049/jimmunol.1000560
14. Ablamunits V, Bisikirka B, Herold KC. Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF. Eur J Immunol (2010) 40(10):2891–901. doi:10.1002/eji.201040485
15. Torrey H, Butterworth J, Mera T, Okubo Y, Wang L, Baum D, et al. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs. Sci Signal (2017) 10:eaaaf868. doi:10.1126/scisignal.aaf8680
16. Chang LY, Lin YC, Chiang JM, Mahalingam J, Su SH, Huang CT, et al. Blockade of TNF-alpha signaling benefits cancer therapy by suppressing effector regulatory T cell expansion. Oncoimmunology (2015) 4(10):e104215. doi:10.2147/oncoimmunol.v5.104215
17. Zaragoza B, Chen X, Oppenheim JJ, Baeyens A, Gregoire S, Chader D, et al. Suppressive activity of human regulatory T cells is maintained in the presence of TNF. Nat Med (2016) 22(1):16–7. doi:10.1038/nm.4019
18. Nguyen DX, Ehrenstein MR. Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNFRII binding in rheumatoid arthritis. J Exp Med (2016) 213(7):1241–53. doi:10.1084/jem.20151255
19. Chopra M, Biehl M, Steinfatt T, Brandl A, Kums J, Amich J, et al. Exogenous TNFR2 activation protects from acute GVHD via host T reg cell expansion. J Exp Med (2016) 213(9):1881–900. doi:10.1084/jem.20151563
20. Leclerc M, Nasrarian S, Pilon C, Thiolat A, Martin GH, Pouchy C, et al. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. Blood (2016) 128(12):1651–9. doi:10.1182/blood-2016-02-700849
21. Pierini A, Strober W, Moffett C, Baker J, Nishikai H, Alvarez M, et al. TNF-alpha priming enhances CD4+Foxp3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. Blood (2016) 128(6):866–71. doi:10.1182/blood-2016-04-711275
22. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol (1995) 5(10):392–9. doi:10.1016/0962-8924(95)00908-1
23. Grell M, Douni E, Löhden M, Clauss M, Maxeiner B, et al. Aminopeptidase P3, a new member of the TNF-TNFR2 signaling complex, confers enhanced tolerance to oxidative stress. Blood (2011) 83(5):793–802. doi:10.1182/blood-2010-09-307041

**ACKNOWLEDGMENTS**

We thank Miss Mingyue Wu and Mr. Chris Chan at Institute of Chinese Medical Sciences, the University of Macau, for technical assistance on flow cytometry cell sorting. We are grateful to Dr. Joost J. Oppenheim at NCI, NIH, for his invaluable input for the preparation of this article.

**FUNDING**

This project was funded by Macau Science and Technology Development Fund (FDCT) research grant 014/2015/A1 and University of Macau research grant MYRG2016-00023-ICMS-QRCM and MYRG2017-00120-ICMS.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.01556/full#supplementary-material.
induces phosphorylation of JNK1 and JNK2. J Cell Sci (2015) 128(4):656–69. doi:10.1242/jcs.149385
25. Faustman DL, Du D. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov (2010) 9:882–93. doi:10.1038/nrd3030
26. So T, Croft M. Regulation of PI-3-kinase and Akt signaling in T lymphocytes and other cells by TNFR family molecules. Front Immunol (2013) 4:139. doi:10.3389/fimmu.2013.00119
27. Adler HS, Kubsch S, Graulich E, Ludwig S, Knop J, Steinbrink K. Activation of MAP kinase p38 is critical for the cell-cycle-controlled suppressor function of regulatory T cells. Blood (2007) 109(10):4351–9. doi:10.1182/blood-2006-09-047563
28. Adler HS, Steinbrink K. MAP kinase p38 and its relation to T cell anergy and suppressor function of regulatory T cells. Cell Cycle (2008) 7(2):169–75. doi:10.4161/cc.7.2.3312
29. Ohkusu-Tsukada K, Toda M, Udono H, Kawakami Y, Takahashi K. Targeted inhibition of IL-10-secreting CD25+ Treg via p38 MAPK suppression in cancer immunotherapy. Eur J Immunol (2010) 40(4):1011–21. doi:10.1002/eji.200939513
30. Lu Y, Zhang M, Wang S, Hong B, Wang Z, Li H, et al. p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat Commun (2014) 5:4229. doi:10.1038/ncomms5229
31. Nagar M, Jacob-Hirsch J, Vernitsky H, Berkun Y, Ben-Horin S, Amariglio N, et al. Targeted inhibition of IL-10-expressing T cells using a small-molecule p38 MAPK inhibitor. Life Sci (2011) 89(21):2138–42. doi:10.1016/j.lfs.2011.05.035
32. Bittner S, Knoll G, Ehrenschwender M. Death receptor 3 signaling enhances proliferation of human regulatory T cells. FEMS Lett (2017) 591(8):1187–95. doi:10.1002/fems.12632
33. Zer C, Sachs G, Shin JM. Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-alpha signaling. Physiol Genomics (2007) 31(2):343–51. doi:10.1152/physiogenomics.00080.2007
34. Chen X, Murakami T, Oppenheim JJ, Howard OMZ. Differential response of murine CD4+CD25+ and CD4+CD25− T cells to dexamethasone-induced cell death. Eur J Immunol (2004) 34:3589–69. doi:10.1002/eji.200324506
35. Wahl C, Liptay S, Adler G, Schmid RM. Sulphasalazine: a potent specific inhibitor of nuclear factor kappa B. J Clin Invest (1998) 101(5):1163–74. doi:10.1172/JCI992
36. Krishnan N, Bencze G, Cohen P, Tonks NK. The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein tyrosine phosphatases. FEMS J (2013) 280(12):2803–11. doi:10.1002/fems.21285
37. Hamano R, Huang J, Yoshimura T, Oppenheim JJ, Chen X. TNF optimally activates regulatory T cells by inducing TNF receptor superfamily members TNFRF2, 4-1BB and OX40. Eur J Immunol (2011) 41(7):2010–20. doi:10.1002/eji.201014205
38. Han J, Lee JD, Bbbs L, Ulevitch R. A MAP kinase targeted by p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy. J Immunol (2008) 180(6):3797–806. doi:10.4049/jimmunol.179.11.7924
39. Kuhlhol C, Herbarth M, Foll J, Staege MS, Kramm C. CD137 stimulation and p38 MAPK inhibition improve reactivity in an in vitro model of glioblastoma immunotherapy. Cancer Immunol Immunother (2013) 62(12):1797–809. doi:10.1007/s00262-013-1484-9
40. Li P, Zheng Y, Chen X. Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol (2017) 8:460. doi:10.3389/fphar.2017.00460
41. Rader AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Grisswolf DE. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, and shock diabetes and immune function. J Pharmacol Exp Ther (1996) 279(3):1453–61.
42. Noubade R, Krementsov DN, Del Río R, Thornton T, Nagaleekar V, Saligrama N, et al. Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmunity. J Immunol (2011) 186(2):3290–300. doi:10.1152/jimmunol.00262.2010.
43. Patterson H, Nibbs R, Mclnnes I, Siebott S. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol (2014) 176(1):1–10. doi:10.1111/cei.12248

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.